Identification of tumors with NRG1 rearrangement, including a
novel putative pathogenic UNC5D-NRG1 gene fusion in prostate
cancer by data-drilling a de-identified tumor database

J 2021

Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database

PTAKOVA, Nikola, Petr MARTINEK, Lubos HOLUBEC, Vaclav JANOVSKY, Jana VANCUROVA et. al.

Základní údaje

Originální název

Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database

Autoři

PTAKOVA, Nikola (203 Česká republika), Petr MARTINEK (203 Česká republika), Lubos HOLUBEC (203 Česká republika), Vaclav JANOVSKY (203 Česká republika), Jana VANCUROVA (203 Česká republika), Petr GROSSMANN (203 Česká republika), Paloma Alcaraz NAVARRO, Juan F. Rodriguez MORENO, Reza ALAGHEHBANDAN, Ondrej HES (203 Česká republika), Ondřej MÁJEK (203 Česká republika, domácí), Milos PESEK (203 Česká republika), Michal MICHAL (203 Česká republika) a Ondrej ONDIC (203 Česká republika, garant)

Vydání

GENES CHROMOSOMES & CANCER, HOBOKEN, WILEY-BLACKWELL, 2021, 1045-2257

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.263

Kód RIV

RIV/00216224:14110/21:00121773

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/gcc.22942

UT WoS

000621111200001

Klíčová slova anglicky

carcinoma; data drilling; ERBB; ERBB3; gene fusion; gene rearrangement; genetics; HER; HER 3; EGF‐ like domain; lung; MAPK; molecular; mRNA sequencing; neuregulin; next‐ generation sequencing; NRG1; PIK

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 6. 2021 09:06, Mgr. Tereza Miškechová

Anotace

V originále

The fusion genes containing neuregulin-1 (NRG1) are newly described potentially actionable oncogenic drivers. Initial clinical trials have shown a positive response to targeted treatment in some cases of NRG1 rearranged lung adenocarcinoma, cholangiocarcinoma, and pancreatic carcinoma. The cost-effective large scale identification of NRG1 rearranged tumors is an open question. We have tested a data-drilling approach by performing a retrospective assessment of a de-identified molecular profiling database of 3263 tumors submitted for fusion testing. Gene fusion detection was performed by RNA-based targeted next-generation sequencing using the Archer Fusion Plex kits for Illumina (ArcherDX Inc., Boulder, CO). Novel fusion transcripts were confirmed by a custom-designed RT-PCR. Also, the aberrant expression of CK20 was studied immunohistochemically. The frequency of NRG1 rearranged tumors was 0.2% (7/3263). The most common histologic type was lung adenocarcinoma (n = 5). Also, renal carcinoma (n = 1) and prostatic adenocarcinoma (n = 1) were found. Identified fusion partners were of a wide range (CD74, SDC4, TNC, VAMP2, UNC5D), with CD74, SDC4 being found twice. The UNC5D is a novel fusion partner identified in prostate adenocarcinoma. There was no co-occurrence with the other tested fusions nor KRAS, BRAF, and the other gene mutations specified in the applied gene panels. Immunohistochemically, the focal expression of CK20 was present in 2 lung adenocarcinomas. We believe it should be considered as an incidental finding. In conclusion, the overall frequency of tumors with NRG1 fusion was 0.2%. All tumors were carcinomas. We confirm (invasive mucinous) lung adenocarcinoma as being the most frequent tumor presenting NRG1 fusion. Herein novel putative pathogenic gene fusion UNC5D-NRG1 is described. The potential role of immunohistochemistry in tumor identification should be further addressed.

Citovat

PTAKOVA, Nikola, Petr MARTINEK, Lubos HOLUBEC, Vaclav JANOVSKY, Jana VANCUROVA, Petr GROSSMANN, Paloma Alcaraz NAVARRO, Juan F. Rodriguez MORENO, Reza ALAGHEHBANDAN, Ondrej HES, Ondřej MÁJEK, Milos PESEK, Michal MICHAL a Ondrej ONDIC. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database. GENES CHROMOSOMES & CANCER. HOBOKEN: WILEY-BLACKWELL, 2021, roč. 60, č. 7, s. 474-481. ISSN 1045-2257. Dostupné z: https://dx.doi.org/10.1002/gcc.22942.

@article{1776205,
   author = {Ptakova, Nikola and Martinek, Petr and Holubec, Lubos and Janovsky, Vaclav and Vancurova, Jana and Grossmann, Petr and Navarro, Paloma Alcaraz and Moreno, Juan F. Rodriguez and Alaghehbandan, Reza and Hes, Ondrej and Májek, Ondřej and Pesek, Milos and Michal, Michal and Ondic, Ondrej},
   article_location = {HOBOKEN},
   article_number = {7},
   doi = {http://dx.doi.org/10.1002/gcc.22942},
   keywords = {carcinoma; data drilling; ERBB; ERBB3; gene fusion; gene rearrangement; genetics; HER; HER 3; EGF‐ like domain; lung; MAPK; molecular; mRNA sequencing; neuregulin; next‐ generation sequencing; NRG1; PIK},
   language = {eng},
   issn = {1045-2257},
   journal = {GENES CHROMOSOMES & CANCER},
   title = {Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/gcc.22942},
   volume = {60},
   year = {2021}
}

TY  - JOUR
ID  - 1776205
AU  - Ptakova, Nikola - Martinek, Petr - Holubec, Lubos - Janovsky, Vaclav - Vancurova, Jana - Grossmann, Petr - Navarro, Paloma Alcaraz - Moreno, Juan F. Rodriguez - Alaghehbandan, Reza - Hes, Ondrej - Májek, Ondřej - Pesek, Milos - Michal, Michal - Ondic, Ondrej
PY  - 2021
TI  - Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database
JF  - GENES CHROMOSOMES & CANCER
VL  - 60
IS  - 7
SP  - 474-481
EP  - 474-481
PB  - WILEY-BLACKWELL
SN  - 10452257
KW  - carcinoma
KW  - data drilling
KW  - ERBB
KW  - ERBB3
KW  - gene fusion
KW  - gene rearrangement
KW  - genetics
KW  - HER
KW  - HER 3
KW  - EGF‐ like domain
KW  - lung
KW  - MAPK
KW  - molecular
KW  - mRNA sequencing
KW  - neuregulin
KW  - next‐ generation sequencing
KW  - NRG1
KW  - PIK
UR  - https://onlinelibrary.wiley.com/doi/10.1002/gcc.22942
N2  - The fusion genes containing neuregulin-1 (NRG1) are newly described potentially actionable oncogenic drivers. Initial clinical trials have shown a positive response to targeted treatment in some cases of NRG1 rearranged lung adenocarcinoma, cholangiocarcinoma, and pancreatic carcinoma. The cost-effective large scale identification of NRG1 rearranged tumors is an open question. We have tested a data-drilling approach by performing a retrospective assessment of a de-identified molecular profiling database of 3263 tumors submitted for fusion testing. Gene fusion detection was performed by RNA-based targeted next-generation sequencing using the Archer Fusion Plex kits for Illumina (ArcherDX Inc., Boulder, CO). Novel fusion transcripts were confirmed by a custom-designed RT-PCR. Also, the aberrant expression of CK20 was studied immunohistochemically. The frequency of NRG1 rearranged tumors was 0.2% (7/3263). The most common histologic type was lung adenocarcinoma (n = 5). Also, renal carcinoma (n = 1) and prostatic adenocarcinoma (n = 1) were found. Identified fusion partners were of a wide range (CD74, SDC4, TNC, VAMP2, UNC5D), with CD74, SDC4 being found twice. The UNC5D is a novel fusion partner identified in prostate adenocarcinoma. There was no co-occurrence with the other tested fusions nor KRAS, BRAF, and the other gene mutations specified in the applied gene panels. Immunohistochemically, the focal expression of CK20 was present in 2 lung adenocarcinomas. We believe it should be considered as an incidental finding. In conclusion, the overall frequency of tumors with NRG1 fusion was 0.2%. All tumors were carcinomas. We confirm (invasive mucinous) lung adenocarcinoma as being the most frequent tumor presenting NRG1 fusion. Herein novel putative pathogenic gene fusion UNC5D-NRG1 is described. The potential role of immunohistochemistry in tumor identification should be further addressed.
ER  -

PTAKOVA, Nikola, Petr MARTINEK, Lubos HOLUBEC, Vaclav JANOVSKY, Jana VANCUROVA, Petr GROSSMANN, Paloma Alcaraz NAVARRO, Juan F. Rodriguez MORENO, Reza ALAGHEHBANDAN, Ondrej HES, Ondřej MÁJEK, Milos PESEK, Michal MICHAL a Ondrej ONDIC. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database. \textit{GENES CHROMOSOMES \&{} CANCER}. HOBOKEN: WILEY-BLACKWELL, 2021, roč.~60, č.~7, s.~474-481. ISSN~1045-2257. Dostupné z: https://dx.doi.org/10.1002/gcc.22942.

Podrobný výpis o publikaci